Skip to content

    Recently Viewed

      Listening...

      Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

      Share Article
      share to

      New Brunswick, NJ (June 5, 2012) – Janssen and Johnson & Johnson will provide investors and other interested parties an overview presentation of results from five pivotal Phase 3 studies evaluating investigational canagliflozin for the treatment of Type 2 Diabetes on Sunday, June 10 at approximately 2:00 p.m., Eastern Time. These data will be presented at the American Diabetes Association annual meeting in Philadelphia, Pa.

      The presentation can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on “Webcasts/Presentations.”

      ###

      Press Contacts:
      Al Wasilewski
      (732) 524-1130

      Bill Price
      (732) 524-6623

      Investor Contacts:
      Stan Panasewicz
      (732) 524-2524

      Louise Mehrotra
      (732) 524-6491

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.